Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) announced a private placement of not more than 59,880,235 on January 6, 2016. The transaction was approved by the China Securities Regulatory Commission. The transaction is subject to a hold period of 36 months expiring May 6, 2019.